Is the Options Market Predicting a Spike in Crescent Capital BDC (CCAP) Stock?
Investors need to pay close attention to Crescent Capital BDC (CCAP) stock based on the movements in the options market lately.
Bargain Alert: I'm Buying These 7-11% Yields For Recurring Income
Market volatility underscores the need for income-producing assets; Crescent Capital BDC and Omega Healthcare Investors offer compelling value with strong fundamentals and attractive yields. Crescent Capital BDC carries a diversified portfolio, high-quality secured debt, robust liquidity, and an 11% dividend yield while trading at a 15% discount to NAV. Omega Healthcare Investors benefits from a stable triple-net lease model, improving operator fundamentals, and a 7.3% dividend yield, with potential for capital appreciation.
I'm Buying Magnificent Dividends Up To 9% Yield
A contrarian mindset can help dividend investors find bargains, with Crescent Capital BDC and Cenovus Energy offering high yields after recent price drops. Crescent Capital BDC carries a diversified debt portfolio, strong dividend coverage, and a safe leverage profile, making it a compelling buy at a 9% discount to book value. Cenovus Energy's integrated operations and cost optimization efforts position it for long-term growth, with plans to return 100% of excess free cash flow to shareholders.
Crescent Capital BDC, Inc. (CCAP) Q4 2024 Earnings Conference Call Transcript
Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q4 2024 Earnings Conference Call February 20, 2025 ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lombard - CFO Conference Call Participants Robert Dodd - Raymond James Mickey Schleien - Ladenburg Paul Johnson - KBW Operator Thank you for standing by. My name is Janine, and I will be your lead operator for today's call.
Crescent Capital BDC (CCAP) Q4 Earnings and Revenues Lag Estimates
Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.61 per share a year ago.
Crescent Capital BDC (CCAP) Expected to Beat Earnings Estimates: Should You Buy?
Crescent Capital BDC (CCAP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Crescent Capital BDC (CCAP) is Poised to Beat Earnings Estimates Again
Crescent Capital BDC (CCAP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Crescent Capital BDC (CCAP) Upgraded to Buy: Here's Why
Crescent Capital BDC (CCAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Crescent Capital: Share Price Finally Catching Up To Fundamentals
Crescent Capital BDC has shown strong price performance, solid financial growth, and high credit quality, making it a fundamentally sound buy despite a challenging economic backdrop. The BDC out-earned its dividend, grew its net asset value, and delivered impressive earnings, beating analysts' estimates with significant year-over-year growth. CCAP's strong balance sheet, with no debt maturing until 2026 and ample liquidity, positions it well for future growth and investment opportunities.
Crescent Capital's Outstanding Dividend Coverage Makes It A Buy
CCAP is a defensive BDC with a 90% concentration on first-lien debt, ensuring high repayment priority during potential litigation processes. The portfolio focuses on non-cyclical businesses (85%), providing safety and predictability of cash flows, and the median EBITDA of its portfolio companies amounts to $27m. CCAP offers substantial distributions, including a $0.42 quarterly dividend per share and additional supplemental distributions, making it an attractive income holding.
Crescent Capital BDC : Material Agreement Form 8 K
Item 1.01. Entry into a Material Definitive Agreement On December 3, 2024, Crescent Capital BDC, Inc. (the "Company") and certain subsidiaries of the Company entered into an Amended and Restated Senior Secured Revolving Credit Agreement (the "Revolving Credit Agreement") with Sumitomo Mitsui Banking Corporation as Administrative Agent ("Agent"), Collateral Agent, Lead Arranger, Sole Bookrunner and a lender, and certain other lenders named therein. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); The Revolving Credit Agreement amended and restated an existing Senior Secured Revolving Credit Agreement with Agent and, among other things, (i) decreased the size of the aggregate revolving commitment from up to $350,000,000.00 to up to $285,000,000.00, (ii) added an initial term commitment in an amount not to exceed $25,000,000.00 for an aggregate facility size of $310,000,000.00, (iii) increased the interest rate by 0.125% so that borrowings under the revolving commitment will bear interest at the applicable benchmark rate plus (A) 1.125% per annum for ABR Loans and 2.125% per annum for Term Benchmark Loans and RFR Loans if the Borrowing Base is less than 1.60 times the Combined Debt Amount and (B) 1.000% per annum for ABR Loans and 2.000% for Term Benchmark Loans and RFR Loans if the Borrowing Base is equal to or greater than 1.60 times the Combined Debt Amount, in each case, on outstanding amounts, or as otherwise determined by the Revolving Credit Agreement, (iii) extended the facility termination date from October 27, 2026 to December 3, 2029, unless otherwise terminated earlier under the Revolving Credit Agreement, and (iv) extended the facility revolving commitment period termination date from October 27, 2025, to December 1, 2028, unless otherwise terminated earlier under the Revolving Credit Agreement. Borrowings under the Revolving Credit Agreement remain subject to leverage restrictions contained in the Investment Company Act of 1940, as amended. The description above is only a summary of the material, amended provisions of the Revolving Credit Agreement and is qualified in its entirety by reference to a copy of the Revolving Credit Agreement, which is filed as Exhibit 10.1 to this current report on Form 8-K.Attachments Original document Permalink DisclaimerCrescent Capital BDC Inc. published this content on December 06, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on December 06, 2024 at 11:02:02.990.
I'm Buying Up To 9% Yield For Recurring Income
Inflation makes Crescent Capital and Crown Castle compelling income-generating investments with yields of 9% and 6%, respectively. Crescent Capital offers a diversified portfolio with a strong 1st lien loan focus, high dividend coverage, and potential for capital appreciation. Crown Castle benefits from growing data demand and AI trends, providing essential infrastructure with a solid balance sheet and attractive valuation.
